Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 178
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Quarterly Psychedelics Briefing: Q3 2026
Weekly Psychedelic Policy Briefing, September 21, 2026
Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity
Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley...
New 3D Structures of Cannabinoid Receptor Inform Safer Drug Design
PT344 – Susan Beaulieu – Epigenetics, Resilience, and Remembering
MindMed Board of Directors Approves Reverse Share Split
COMPASS Pathways plc announces second quarter 2022 financial results and business...
MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference
Canadian Patent Grant Strengthens Small Pharma’s International Position
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough...
Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health...
Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A
Load more